Santhera Seeks Canadian Approval for Friedreich's Ataxia Drug
Posted on: Tuesday, 25 September 2007, 15:00 CDT
Santhera Pharmaceuticals is planning to file a new drug submission for Idebenone for the treatment of Friedreich's ataxia.
Following a recent meeting with the Therapeutic Products Directorate (TPD) of Health Canada, and after the receipt of the positive decision on eligibility, Santhera now has 60 days to submit the NDS to the Canadian regulatory authorities.
Klaus Schollmeier, CEO said: "We are excited about Health Canada's decision. We will seek Canadian market approval with a safety and efficacy package that is equivalent to the file currently under review at the EMEA. If everything goes according to plan, we may be able to launch SNT-MC17 in the Canadian market in late 2008, thus providing FRDA patients with the first approved pharmaceutical product for the treatment of this devastating disease."
Source: Datamonitor
Related Articles
- Government Says a Wealthy Canadian Businessman Was Kidnapped, Killed in Iraq
- Dosanjh Defends Canadian Health Care Despite Court Ruling, Foreign Comparison
- Canadian Hospitals Not Prepared for Disaster, Say Emergency-Care Doctors
- Canadian Pacific Railway Enjoys Profitable 'Sunshine' After Years of Cutbacks
- Canadians in Kandahar Take Different Approach to Aid Than U.S. Counterparts
- West Nile Virus Detected in Blood Donated in Ottawa: Canadian Blood Services
- Seabird Droppings Raising DDT, Mercury Levels in Arctic: Canadian Study
- U.S. Government in Seattle Court Seeking to Reopen Border to Canadian Cattle
- Canadian Officials Offered Intelligence to Syrians Despite Torture Fears
- Number of Canadians Claiming to Be in Good Health Falling, Report Finds
 |
 |
User Comments (0)
RSS Feeds